STOCK TITAN

Fortress Biotech, Inc. - FBIO STOCK NEWS

Welcome to our dedicated page for Fortress Biotech news (Ticker: FBIO), a resource for investors and traders seeking the latest updates and insights on Fortress Biotech stock.

Fortress Biotech, Inc. (symbol: FBIO) is a pioneering biopharmaceutical company focused on acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products. The company operates through a unique model of establishing subsidiary companies, collectively known as Fortress companies, to promote research, development, and commercialization efforts.

Fortress Biotech leverages its deep expertise in the biopharmaceutical industry and drug development to support its subsidiaries. The company offers funding, management services, and strategic guidance to bolster the success of its Fortress companies. This collaborative approach enables the subsidiaries to focus on breakthrough innovations while benefiting from Fortress Biotech's resources and infrastructure.

The company's diverse product portfolio includes several key products such as Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. These products span across therapeutic areas with a significant focus on dermatology, where Fortress derives the majority of its revenue. Beyond dermatology, the company and its subsidiaries are deeply engaged in biotechnology, pharmaceutical development, oncology, and therapeutics.

Fortress Biotech continuously seeks strategic partnerships, licensing opportunities, joint ventures, and public and private financing to accelerate and support its research and development programs. These collaborations aim to enhance the company's capacity to bring novel treatments to market and address unmet medical needs.

For the latest updates and events, including financial results discussions and corporate updates, Fortress Biotech frequently engages with its stakeholders through conference calls and press releases.

For more information or media inquiries, please contact:
Jaclyn Jaffe, Fortress Biotech, Inc.: (781) 652-4500, ir@fortressbiotech.com
Tony Plohoros, 6 Degrees: (908) 591-2839, tplohoros@6degreespr.com

Rhea-AI Summary
Fortress Biotech to present corporate overview at ROTH MKM 2023 Healthcare Opportunities Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences
-
Rhea-AI Summary
Fortress Biotech to present corporate overview at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Journey Medical enters exclusive license agreement with Maruho Co., Ltd. for Qbrexza in multiple territories
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.68%
Tags
none
Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) announced total net revenue of $17.4 million in Q2 2023, a 40% increase from Q1 2023. Positive results were achieved in Phase 3 clinical trials for DFD-29 and cosibelimab. Two NDA submissions for DFD-29 and CUTX-101 are anticipated in H2 2023. The PDUFA goal date for cosibelimab is January 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
-
Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) announced a 41% increase in total net revenues to $17.2 million in Q2 2023, and positive topline results from two Phase 3 clinical trials evaluating DFD-29 for papulopustular rosacea treatment. The company plans to submit an NDA to the FDA for DFD-29 in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
conferences
Rhea-AI Summary
DERM: Journey Medical Corporation to Discuss Positive Topline Clinical Data and Financial Results in Upcoming Conference Call on August 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
-
Rhea-AI Summary
Journey Medical Corporation will release its second quarter 2023 financial results during the week of August 7, 2023. The company will also host a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-

FAQ

What is the current stock price of Fortress Biotech (FBIO)?

The current stock price of Fortress Biotech (FBIO) is $1.61 as of November 22, 2024.

What is the market cap of Fortress Biotech (FBIO)?

The market cap of Fortress Biotech (FBIO) is approximately 43.6M.

What does Fortress Biotech, Inc. do?

Fortress Biotech acquires, develops, and commercializes innovative pharmaceutical and biotechnology products.

What are Fortress companies?

Fortress companies are subsidiaries established by Fortress Biotech to focus on specialized research, development, and commercialization of biotech products.

What products does Fortress Biotech offer?

Fortress Biotech's portfolio includes Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm.

How does Fortress Biotech support its subsidiaries?

Fortress Biotech provides funding, management services, and strategic guidance to support the growth and success of its subsidiaries.

What is the primary revenue source for Fortress Biotech?

The majority of Fortress Biotech's revenue comes from its dermatology segment.

Does Fortress Biotech engage in partnerships?

Yes, Fortress Biotech frequently seeks licensing, partnerships, joint ventures, and public and private financings to support its development programs.

Which therapeutic areas does Fortress Biotech focus on?

Fortress Biotech and its subsidiaries focus on dermatology, biotechnology, pharmaceutical development, oncology, and therapeutics.

How can I get the latest news on Fortress Biotech?

You can stay updated by following Fortress Biotech's press releases and participating in their conference calls.

Who can I contact for more information about Fortress Biotech?

For more information, contact Jaclyn Jaffe at Fortress Biotech or Tony Plohoros at 6 Degrees.

Where can I find financial updates from Fortress Biotech?

Financial updates are provided through conference calls and press releases hosted by Fortress Biotech.

Fortress Biotech, Inc.

Nasdaq:FBIO

FBIO Rankings

FBIO Stock Data

43.62M
21.76M
21.21%
15.78%
9.51%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BAY HARBOR ISLANDS